Celgene
Search results
Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.
Juno Therapeutics, Inc. | 27,648 followers on LinkedIn. We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver...
Feb 8, 2022 · When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune...
Details. Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Feb 5, 2021 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphom...
Jan 22, 2018 · JCARH125 will enhance Celgene’s campaign against BCMA (B-cell maturation antigen), a key target in multiple myeloma. Additional cellular therapy assets in proof-of-concept trials for hematologic malignancies and solid tumors will add to Celgene’s existing pipeline.
Nov 1, 2017 · Shares in Juno Therapeutics jumped by more than 8 per cent on Wednesday after the release of clinical trial data ahead of a closely-watched medical meeting this weekend.
Nov 2, 2017 · SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that 15 abstracts detailing updated clinical and preclinical results from the company and its collaborators will be presented at the 59 th American Society of ...
Sep 12, 2016 · We consider Juno Therapeutics as the future leader in CAR-T and TCR space due to its next generation technologies like 3rd and 4th generation CARs, armored CARs, TCRs and potential to combine...
Jan 22, 2018 · Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.
